Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 barzolvolimab study in cold-induced urticaria and symptomatic dermographism
2025-522583-32-00Phase 3Authorised
- Sponsor
- Celldex Therapeutics
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in Cold urticaria (CU) and symptomatic dermatographism (SD) comparing Barzolvolimab with Placebo (2 arms). Planned start Mar 2026; status: authorised.
02
Drugs
barzolvolimab
03
Conditions
Cold urticaria (CU)symptomatic dermatographism (SD)
Beyond the preview
Go deeper on 2025-522583-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522583-32-00.